Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
NYSE MKT:PLX
Holding PLX?
Track your performance easily
PLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.82 - $1.90
Previous Close$1.66
Volume545.89K
Average Volume (3M)242.43K
Market Cap
$122.23M
Enterprise Value$100.51M
Total Cash (Recent Filing)$27.41M
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Mar 13, 2025EPS Estimate
$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding73,633,583
10 Day Avg. Volume641,998
30 Day Avg. Volume242,433
Standard Deviation0.18
R-Squared0.04
Alpha-0.00372
Financial Highlights & Ratios
Price to Book (P/B)3.84
Price to Sales (P/S)2.63
Price to Cash Flow (P/CF)7.30
P/FCF Ratio7.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda-13.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Protalix News
PremiumCompany Announcements
Protalix BioTherapeutics Reports Strong Q3 2024 Results
PremiumCompany Announcements
Protalix to Present Promising PRX-115 Trial Data
Ownership Overview
4.29% Insiders
0.80% Mutual Funds
0.93% Other Institutional Investors
93.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $0.82 and its highest was $1.90 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Currently, no data Available
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 109 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Nov 14, 2024. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by -$0.03.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is $0.08.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 73,633,580 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.03 in its last earnings report, missing expectations of $0.06. Following the earnings report the stock price went up 13.71%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Among the largest hedge funds holding Protalix Biotherapeutics’s share is Highbridge Capital Management LLC. It holds Protalix Biotherapeutics’s shares valued at N/A.
---
Protalix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.73%
12-Months-Change
Fundamentals
Return on Equity
-27.18%
Trailing 12-Months
Asset Growth
-29.70%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
---
PLX Earnings Call
Q3 2024
0:00 / 0:00
---
PLX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---